-
Science - Translational Medicine: Novel Biomarkers for Triple Negative Breast Cancer
Time of Update: 2022-08-15
Researchers at the Johns Hopkins University School of Medicine have focused on triple-negative breast cancer (TNBC) to uncover key molecular differences between primary and metastatic cancer cells .
-
Baylor College of Medicine discovers new target for triple-negative breast cancer: MAPK4
Time of Update: 2022-01-21
In a study published today in Nature Communications, scientists at Baylor College of Medicine and other institutions report that MAPK4 appears to play an important role in triple-negative breast cancer .
MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade.
-
The European Commission on Medicines for Human Use (CHMP) has positive opinions on sacituzumab
Time of Update: 2021-10-20
Breast cancer diagnosis Sacituzumab govitecan is a first-class Trop-2 targeted antibody drug conjugate .
Sacituzumab govitecan is a first-class Trop-2 targeted antibody drug conjugate .
Sacituzumab govitecan is a first-class Trop-2 targeted antibody drug conjugate .
-
Danaher Helps Boao Lecheng Pioneer Zone to Realize the "Triple Synchronization" of Technology, Equipment and Medicine
Time of Update: 2021-07-10
Wei Chunyan, Vice President of Chinese Government Affairs of Danaher, said that this time, Danaher brought a group of innovative products to participate in Boao Lecheng Phase II "Never Ending" International Pharmaceutical Equipment Exhibition, and provided medical solutions in multiple fields, also in order to respond positively.
-
Breathe new medicine! GSK single inhaler triple therapy Trelegy Ellipta has been approved by the European Union to expand chronic pulmonary estration
Time of Update: 2021-02-14
British pharmaceutical giant GlaxoSmithKline (GSK) and partner Innoviva recently announced that the European Commission (EC) has approved an extension of the triple therapy Trelegy Ellipta (FF/UMEC/VI) label for chronic obstructive pulmonary disease (COPD) Treatment of patients, specifically: receiving a double bronchid dilate or an inhaled corticosteroid (ICS) and a long-acting beta-2 astration (LABA) in a combined treatment of moderate to severe COPD patients who did not adequately control the condition.
-
Chinese COPD innovative medicine! AstraZeneca's innovative triple inhaler budigor is officially launched for COPD maintenance treatment!
Time of Update: 2020-01-13
January 13, 2020 / BIOON / -- AstraZeneca recently announced that the triple new drug budigor inhaled aerosol of copf was officially launched in China Budesonide inhaled aerosol adopts innovative co s
-
ACS Nano: Li Yaping's team from Shanghai Institute of Medicine found that light activated
Time of Update: 2018-03-28
Three negative breast cancer (TNBC) has high heterogeneity There are a large number of mesenchymal cells with high metastatic capacity in its core and rapidly proliferating cells in its periphery Ther
-
%, and the number of traditional Chinese medicine on the market has tripled
Time of Update: 2016-01-29
Source: insight database 2016-01-28 policy upheaval in 2015, generic drugs and imported drugs declaration shrank, CDE also made full efforts to review, so how many drugs were approved by CFDA in this